MARKET

MLYS

MLYS

Mineralys Therapeutics, Inc.
NASDAQ
15.98
+0.46
+2.96%
Opening 14:12 11/11 EST
OPEN
15.79
PREV CLOSE
15.52
HIGH
16.11
LOW
15.25
VOLUME
756.08K
TURNOVER
--
52 WEEK HIGH
47.65
52 WEEK LOW
14.91
MARKET CAP
1.42B
P/E (TTM)
-3.6640
1D
5D
1M
3M
1Y
5Y
1D
Is Long Term Blood Pressure Data Altering The Investment Case For Mineralys Therapeutics (MLYS)?
Simply Wall St · 12h ago
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and ImmunityBio (IBRX)
TipRanks · 2d ago
Mineralys' Lorundrostat Sustains Blood Pressure Reduction Through 48 Weeks
NASDAQ · 2d ago
Weekly Report: what happened at MLYS last week (1102-1106)?
Weekly Report · 2d ago
Mineralys Therapeutics (MLYS) Could Be 66% Undervalued Following Long Term Trial Data
Simply Wall St · 2d ago
Mineralys Therapeutics announces long-term results from Transform-HTN trial
TipRanks · 2d ago
Mineralys Therapeutics, Inc. (MLYS) Gets a Buy from Wells Fargo
TipRanks · 5d ago
Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)
Seeking Alpha · 6d ago
More
About MLYS
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.

Webull offers Mineralys Therapeutics Inc stock information, including NASDAQ: MLYS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLYS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MLYS stock methods without spending real money on the virtual paper trading platform.